Objectives:

• Identify current patient populations and treatments for multiple sclerosis (MS)
• Determine current and anticipated future use of Tysabri
• Distinguish the target population for Tysabri in both countries using Tysabri (Germany and the United Kingdom) and countries anticipating its future use (Italy, Spain, and France)
• Understand the risk of progressive multifocal leukoencephalopathy (PML) as a side effect of Tysabri use
• Clarify anticipated future treatment regimens for relapsing remitting MS patients

Products Highlighted:

• Tysabri

Topics:

• MS treatment patterns
• Evaluation of Tysabri
• PML (Progressive Multifocal Leukoencephalopathy) as a side effect of Tysabri
• Future practice patterns of neurologists

Screening Criteria:

• The total sample comprises 46 neurologists
• 12 neurologists from Italy, Spain, and France
• 34 neurologists from Germany and the United Kingdom
• Have been in practice between 2 and 30 years
• Spend at least 50% of their professional time in clinical practice
• Currently manage at least 50 MS patients